{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:59:59Z","timestamp":1793105999735,"version":"4.5.0"},"reference-count":278,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epigenetic mechanisms play vital roles not only in cancer initiation and progression, but also in the activation, differentiation and effector function(s) of immune cells. In this review, we summarize current literature related to epigenomic dynamics in immune cells impacting immune cell fate and functionality, and the immunogenicity of cancer cells. Some important immune-associated genes, such as granzyme B, IFN-\u03b3, IL-2, IL-12, FoxP3 and STING, are regulated via epigenetic mechanisms in immune or\/and cancer cells, as are immune checkpoint molecules (PD-1, CTLA-4, TIM-3, LAG-3, TIGIT) expressed by immune cells and tumor-associated stromal cells. Thus, therapeutic strategies implementing epigenetic modulating drugs are expected to significantly impact the tumor microenvironment (TME) by promoting transcriptional and metabolic reprogramming in local immune cell populations, resulting in inhibition of immunosuppressive cells (MDSCs and Treg) and the activation of anti-tumor T effector cells, professional antigen presenting cells (APC), as well as cancer cells which can serve as non-professional APC. In the latter instance, epigenetic modulating agents may coordinately promote tumor immunogenicity by inducing de novo expression of transcriptionally repressed tumor-associated antigens, increasing expression of neoantigens and MHC processing\/presentation machinery, and activating tumor immunogenic cell death (ICD). ICD provides a rich source of immunogens for anti-tumor T cell cross-priming and sensitizing cancer cells to interventional immunotherapy. In this way, epigenetic modulators may be envisioned as effective components in combination immunotherapy approaches capable of mediating superior therapeutic efficacy.<\/jats:p>","DOI":"10.1186\/s12943-021-01464-x","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T08:10:52Z","timestamp":1639987852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":325,"title":["Epigenetic modulation of antitumor immunity for improved cancer immunotherapy"],"prefix":"10.1186","volume":"20","author":[{"given":"Enyong","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shudipto","family":"Wahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Storkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-9907","authenticated-orcid":false,"given":"Zong Sheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"1464_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","volume":"128","author":"PA Jones","year":"2007","unstructured":"Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683\u201392.","journal-title":"Cell"},{"key":"1464_CR2","doi-asserted-by":"publisher","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","volume":"357","author":"WA Flavahan","year":"2017","unstructured":"Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357:eaal2380.","journal-title":"Science"},{"key":"1464_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/0008-5472.CAN-19-0924","volume":"80","author":"M Yu","year":"2020","unstructured":"Yu M, Hazelton WD, Luebeck GE, Grady WM. Epigenetic aging: more than just a clock when it comes to cancer. Cancer Res. 2020;80:367\u201374.","journal-title":"Cancer Res"},{"key":"1464_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-Zugich","year":"2018","unstructured":"Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19:10\u20139.","journal-title":"Nat Immunol"},{"key":"1464_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1126\/science.1083558","volume":"300","author":"F Gaudet","year":"2003","unstructured":"Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, et al. Induction of tumors in mice by genomic hypomethylation. Science. 2003;300:489\u201392.","journal-title":"Science"},{"key":"1464_CR6","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1158\/0008-5472.CAN-08-3351","volume":"69","author":"HJ Jun","year":"2009","unstructured":"Jun HJ, Woolfenden S, Coven S, Lane K, Bronson R, Housman D, et al. Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas. Cancer Res. 2009;69:2180\u20134.","journal-title":"Cancer Res"},{"key":"1464_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nri2487","volume":"9","author":"CB Wilson","year":"2009","unstructured":"Wilson CB, Rowell E, Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol. 2009;9:91\u2013105.","journal-title":"Nat Rev Immunol"},{"key":"1464_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/ni.3688","volume":"18","author":"B Kakaradov","year":"2017","unstructured":"Kakaradov B, Arsenio J, Widjaja CE, He Z, Aigner S, Metz PJ, et al. Early transcriptional and epigenetic regulation of CD8(+) T cell differentiation revealed by single-cell RNA sequencing. Nat Immunol. 2017;18:422\u201332.","journal-title":"Nat Immunol"},{"key":"1464_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nri3777","volume":"15","author":"D Alvarez-Errico","year":"2015","unstructured":"Alvarez-Errico D, Vento-Tormo R, Sieweke M, Ballestar E. Epigenetic control of myeloid cell differentiation, identity and function. Nat Rev Immunol. 2015;15:7\u201317.","journal-title":"Nat Rev Immunol"},{"key":"1464_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nri.2017.146","volume":"18","author":"AN Henning","year":"2018","unstructured":"Henning AN, Roychoudhuri R, Restifo NP. Epigenetic control of CD8(+) T cell differentiation. Nat Rev Immunol. 2018;18:340\u201356.","journal-title":"Nat Rev Immunol"},{"key":"1464_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/carcin\/bgn017","volume":"29","author":"JD Licchesi","year":"2008","unstructured":"Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis. 2008;29:895\u2013904.","journal-title":"Carcinogenesis"},{"key":"1464_CR12","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1073\/pnas.94.10.5367","volume":"94","author":"K Okamoto","year":"1997","unstructured":"Okamoto K, Morison IM, Taniguchi T, Reeve AE. Epigenetic changes at the insulin-like growth factor II\/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc Natl Acad Sci U S A. 1997;94:5367\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1464_CR13","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-1127-3","volume":"10","author":"DJ Simpson","year":"2004","unstructured":"Simpson DJ, McNicol AM, Murray DC, Bahar A, Turner HE, Wass JA, et al. Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease. Clin Cancer Res. 2004;10:1780\u20138.","journal-title":"Clin Cancer Res"},{"key":"1464_CR14","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41586-020-03147-x","volume":"590","author":"D Alonso-Curbelo","year":"2021","unstructured":"Alonso-Curbelo D, Ho YJ, Burdziak C, Maag JLV, Morris JP, Chandwani R, et al. A gene-environment-induced epigenetic program initiates tumorigenesis. Nature. 2021;590:642\u20138.","journal-title":"Nature"},{"key":"1464_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrg1748","volume":"7","author":"AP Feinberg","year":"2006","unstructured":"Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7:21\u201333.","journal-title":"Nat Rev Genet"},{"key":"1464_CR16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrg.2016.13","volume":"17","author":"AP Feinberg","year":"2016","unstructured":"Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17:284\u201399.","journal-title":"Nat Rev Genet"},{"key":"1464_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd1930","volume":"5","author":"CB Yoo","year":"2006","unstructured":"Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"1464_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.biocel.2008.08.020","volume":"41","author":"A Mai","year":"2009","unstructured":"Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol. 2009;41:199\u2013213.","journal-title":"Int J Biochem Cell Biol"},{"key":"1464_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1515\/bmc.2010.020","volume":"1","author":"XD Yu","year":"2010","unstructured":"Yu XD, Guo ZS. Epigenetic drugs for cancer treatment and prevention: mechanisms of action. Biomol Concepts. 2010;1:239\u201351.","journal-title":"Biomol Concepts"},{"key":"1464_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature13905","volume":"518","author":"CJ Cheng","year":"2015","unstructured":"Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 2015;518:107\u201310.","journal-title":"Nature"},{"key":"1464_CR21","first-page":"1354","volume":"9","author":"MC Jiang","year":"2019","unstructured":"Jiang MC, Ni JJ, Cui WY, Wang BY, Zhuo W. Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 2019;9:1354\u201366.","journal-title":"Am J Cancer Res"},{"key":"1464_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrg3230","volume":"13","author":"PA Jones","year":"2012","unstructured":"Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484\u201392.","journal-title":"Nat Rev Genet"},{"key":"1464_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19:81\u201392.","journal-title":"Nat Rev Genet"},{"key":"1464_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","volume":"70","author":"M Kulis","year":"2010","unstructured":"Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27\u201356.","journal-title":"Adv Genet"},{"key":"1464_CR25","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37:1012\u201327.","journal-title":"Trends Genet"},{"key":"1464_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nature12750","volume":"502","author":"RM Kohli","year":"2013","unstructured":"Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502:472\u20139.","journal-title":"Nature"},{"key":"1464_CR27","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1038\/emm.2017.5","volume":"49","author":"J An","year":"2017","unstructured":"An J, Rao A, Ko M. TET family dioxygenases and DNA demethylation in stem cells and cancers. Exp Mol Med. 2017;49:e323.","journal-title":"Exp Mol Med"},{"key":"1464_CR28","doi-asserted-by":"publisher","first-page":"623948","DOI":"10.3389\/fcell.2020.623948","volume":"8","author":"NJ Tsiouplis","year":"2020","unstructured":"Tsiouplis NJ, Bailey DW, Chiou LF, Wissink FJ, Tsagaratou A. TET-mediated epigenetic regulation in immune cell development and disease. Front Cell Dev Biol. 2020;8:623948.","journal-title":"Front Cell Dev Biol"},{"key":"1464_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1101\/gad.276568.115","volume":"30","author":"KD Rasmussen","year":"2016","unstructured":"Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30:733\u201350.","journal-title":"Genes Dev"},{"key":"1464_CR30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.trecan.2020.12.011","volume":"7","author":"JK Bray","year":"2021","unstructured":"Bray JK, Dawlaty MM, Verma A, Maitra A. Roles and regulations of TET enzymes in solid tumors. Trends Cancer. 2021;7:635\u201346.","journal-title":"Trends Cancer"},{"key":"1464_CR31","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrg.2017.33","volume":"18","author":"X Wu","year":"2017","unstructured":"Wu X, Zhang Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet. 2017;18:517\u201334.","journal-title":"Nat Rev Genet"},{"key":"1464_CR32","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/ni.3148","volume":"16","author":"L Cimmino","year":"2015","unstructured":"Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol. 2015;16:653\u201362.","journal-title":"Nat Immunol"},{"key":"1464_CR33","doi-asserted-by":"publisher","first-page":"10071","DOI":"10.1038\/ncomms10071","volume":"6","author":"J An","year":"2015","unstructured":"An J, Gonzalez-Avalos E, Chawla A, Jeong M, Lopez-Moyado IF, Li W, et al. Acute loss of TET function results in aggressive myeloid cancer in mice. Nat Commun. 2015;6:10071.","journal-title":"Nat Commun"},{"key":"1464_CR34","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","volume":"170","author":"L Cimmino","year":"2017","unstructured":"Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170:1079\u20131095 e20.","journal-title":"Cell"},{"key":"1464_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4049\/jimmunol.1700559","volume":"200","author":"SA Carty","year":"2018","unstructured":"Carty SA, Gohil M, Banks LB, Cotton RM, Johnson ME, Stelekati E, et al. The loss of TET2 promotes CD8(+) T cell memory differentiation. J Immunol. 2018;200:82\u201391.","journal-title":"J Immunol"},{"key":"1464_CR36","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307\u201312.","journal-title":"Nature"},{"key":"1464_CR37","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1021\/cr500350x","volume":"115","author":"GD Bowman","year":"2015","unstructured":"Bowman GD, Poirier MG. Post-translational modifications of histones that influence nucleosome dynamics. Chem Rev. 2015;115:2274\u201395.","journal-title":"Chem Rev"},{"key":"1464_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/ni0710-565","volume":"11","author":"A Tarakhovsky","year":"2010","unstructured":"Tarakhovsky A. Tools and landscapes of epigenetics. Nat Immunol. 2010;11:565\u20138.","journal-title":"Nat Immunol"},{"key":"1464_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41392-019-0095-0","volume":"4","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62.","journal-title":"Signal Transduct Target Ther"},{"key":"1464_CR40","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMra1805035","volume":"383","author":"SE Bates","year":"2020","unstructured":"Bates SE. Epigenetic therapies for Cancer. N Engl J Med. 2020;383:650\u201363.","journal-title":"N Engl J Med"},{"key":"1464_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.biochem.70.1.81","volume":"70","author":"SY Roth","year":"2001","unstructured":"Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem. 2001;70:81\u2013120.","journal-title":"Annu Rev Biochem"},{"key":"1464_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-016-0225-2","volume":"8","author":"H Wapenaar","year":"2016","unstructured":"Wapenaar H, Dekker FJ. Histone acetyltransferases: challenges in targeting bi-substrate enzymes. Clin Epigenetics. 2016;8:59.","journal-title":"Clin Epigenetics"},{"key":"1464_CR43","doi-asserted-by":"publisher","first-page":"e1800078","DOI":"10.1002\/bies.201800078","volume":"40","author":"AK Voss","year":"2018","unstructured":"Voss AK, Thomas T. Histone lysine and genomic targets of histone acetyltransferases in mammals. Bioessays. 2018;40:e1800078.","journal-title":"Bioessays"},{"key":"1464_CR44","doi-asserted-by":"publisher","first-page":"18439","DOI":"10.1073\/pnas.2009316117","volume":"117","author":"W Ren","year":"2020","unstructured":"Ren W, Fan H, Grimm SA, Guo Y, Kim JJ, Yin J, et al. Direct readout of heterochromatic H3K9me3 regulates DNMT1-mediated maintenance DNA methylation. Proc Natl Acad Sci U S A. 2020;117:18439\u201347.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1464_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13059-019-1870-5","volume":"20","author":"Z Zhao","year":"2019","unstructured":"Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20:245.","journal-title":"Genome Biol"},{"key":"1464_CR46","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6:a018713.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1464_CR47","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj20021321","volume":"370","author":"AJ de Ruijter","year":"2003","unstructured":"de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737\u201349.","journal-title":"Biochem J"},{"key":"1464_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30\u20139.","journal-title":"J Clin Invest"},{"key":"1464_CR49","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6:a026831.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1464_CR50","doi-asserted-by":"publisher","first-page":"576946","DOI":"10.3389\/fcell.2020.576946","volume":"8","author":"G Li","year":"2020","unstructured":"Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol. 2020;8:576946.","journal-title":"Front Cell Dev Biol"},{"key":"1464_CR51","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41577-018-0037-z","volume":"18","author":"W Ellmeier","year":"2018","unstructured":"Ellmeier W, Seiser C. Histone deacetylase function in CD4(+) T cells. Nat Rev Immunol. 2018;18:617\u201334.","journal-title":"Nat Rev Immunol"},{"key":"1464_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis. Mol Cancer. 2020;19:5.","journal-title":"Mol Cancer"},{"key":"1464_CR53","doi-asserted-by":"publisher","first-page":"e20191453","DOI":"10.1084\/jem.20191453","volume":"217","author":"RE Tay","year":"2020","unstructured":"Tay RE, Olawoyin O, Cejas P, Xie Y, Meyer CA, Ito Y, et al. Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. J Exp Med. 2020;217:e20191453.","journal-title":"J Exp Med"},{"key":"1464_CR54","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1128\/MCB.25.8.2873-2884.2005","volume":"25","author":"XJ Yang","year":"2005","unstructured":"Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol. 2005;25:2873\u201384.","journal-title":"Mol Cell Biol"},{"key":"1464_CR55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-018-0654-9","volume":"11","author":"T Li","year":"2018","unstructured":"Li T, Zhang C, Hassan S, Liu X, Song F, Chen K, et al. Histone deacetylase 6 in cancer. J Hematol Oncol. 2018;11:111.","journal-title":"J Hematol Oncol"},{"key":"1464_CR56","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-19-3738","volume":"80","author":"D Banik","year":"2020","unstructured":"Banik D, Noonepalle S, Hadley M, Palmer E, Gracia-Hernandez M, Zevallos-Delgado C, et al. HDAC6 plays a noncanonical role in the regulation of antitumor immune responses, dissemination, and invasiveness of breast cancer. Cancer Res. 2020;80:3649\u201362.","journal-title":"Cancer Res"},{"key":"1464_CR57","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41598-019-57294-x","volume":"10","author":"S Dahiya","year":"2020","unstructured":"Dahiya S, Beier UH, Wang L, Han R, Jiao J, Akimova T, et al. HDAC10 deletion promotes Foxp3(+) T-regulatory cell function. Sci Rep. 2020;10:424.","journal-title":"Sci Rep"},{"key":"1464_CR58","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/0008-5472.CAN-13-2584","volume":"74","author":"G Liu","year":"2014","unstructured":"Liu G, Bi Y, Shen B, Yang H, Zhang Y, Wang X, et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1alpha-dependent glycolysis. Cancer Res. 2014;74:727\u201337.","journal-title":"Cancer Res"},{"key":"1464_CR59","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1158\/1535-7163.MCT-09-0971","volume":"9","author":"B Peck","year":"2010","unstructured":"Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther. 2010;9:844\u201355.","journal-title":"Mol Cancer Ther"},{"key":"1464_CR60","first-page":"54","volume":"2018","author":"C Yanginlar","year":"1861","unstructured":"Yanginlar C, Logie C. HDAC11 is a regulator of diverse immune functions. Biochim Biophys Acta Gene Regul Mech. 1861;2018:54\u20139.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"1464_CR61","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1189\/jlb.1A0415-176RRR","volume":"102","author":"E Sahakian","year":"2017","unstructured":"Sahakian E, Chen J, Powers JJ, Chen X, Maharaj K, Deng SL, et al. Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. J Leukoc Biol. 2017;102:475\u201386.","journal-title":"J Leukoc Biol"},{"key":"1464_CR62","doi-asserted-by":"publisher","first-page":"8626","DOI":"10.1038\/s41598-017-09211-3","volume":"7","author":"J Huang","year":"2017","unstructured":"Huang J, Wang L, Dahiya S, Beier UH, Han R, Samanta A, et al. Histone\/protein deacetylase 11 targeting promotes Foxp3+ Treg function. Sci Rep. 2017;7:8626.","journal-title":"Sci Rep"},{"key":"1464_CR63","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/blood-2016-08-731505","volume":"130","author":"DM Woods","year":"2017","unstructured":"Woods DM, Woan KV, Cheng F, Sodre AL, Wang D, Wu Y, et al. T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood. 2017;130:146\u201355.","journal-title":"Blood"},{"key":"1464_CR64","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1073\/pnas.1815365116","volume":"116","author":"J Cao","year":"2019","unstructured":"Cao J, Sun L, Aramsangtienchai P, Spiegelman NA, Zhang X, Huang W, et al. HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2. Proc Natl Acad Sci U S A. 2019;116:5487\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1464_CR65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","volume":"8","author":"A Stathis","year":"2018","unstructured":"Stathis A, Bertoni F. BET proteins as targets for anticancer treatment. Cancer Discov. 2018;8:24\u201336.","journal-title":"Cancer Discov"},{"key":"1464_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrc3409","volume":"13","author":"Y Yang","year":"2013","unstructured":"Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013;13:37\u201350.","journal-title":"Nat Rev Cancer"},{"key":"1464_CR67","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1038\/emm.2017.11","volume":"49","author":"K Hyun","year":"2017","unstructured":"Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017;49:e324.","journal-title":"Exp Mol Med"},{"key":"1464_CR68","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.15252\/embr.201541113","volume":"16","author":"E Dimitrova","year":"2015","unstructured":"Dimitrova E, Turberfield AH, Klose RJ. Histone demethylases in chromatin biology and beyond. EMBO Rep. 2015;16:1620\u201339.","journal-title":"EMBO Rep"},{"key":"1464_CR69","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1126\/science.aau5870","volume":"363","author":"M Batie","year":"2019","unstructured":"Batie M, Frost J, Frost M, Wilson JW, Schofield P, Rocha S. Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science. 2019;363:1222\u20136.","journal-title":"Science"},{"key":"1464_CR70","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1021\/acs.chemrev.6b00801","volume":"118","author":"HU Kaniskan","year":"2018","unstructured":"Kaniskan HU, Martini ML, Jin J. Inhibitors of protein methyltransferases and demethylases. Chem Rev. 2018;118:989\u20131068.","journal-title":"Chem Rev"},{"key":"1464_CR71","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1038\/s41467-019-11282-x","volume":"10","author":"Z Ji","year":"2019","unstructured":"Ji Z, Sheng Y, Miao J, Li X, Zhao H, Wang J, et al. The histone methyltransferase Setd2 is indispensable for V(D)J recombination. Nat Commun. 2019;10:3353.","journal-title":"Nat Commun"},{"key":"1464_CR72","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.immuni.2019.01.003","volume":"50","author":"V Adoue","year":"2019","unstructured":"Adoue V, Binet B, Malbec A, Fourquet J, Romagnoli P, van Meerwijk JPM, et al. The histone methyltransferase SETDB1 controls T helper cell lineage integrity by repressing endogenous retroviruses. Immunity. 2019;50:629\u2013644 e8.","journal-title":"Immunity"},{"key":"1464_CR73","doi-asserted-by":"publisher","first-page":"108504","DOI":"10.1016\/j.celrep.2020.108504","volume":"33","author":"L Kealy","year":"2020","unstructured":"Kealy L, Di Pietro A, Hailes L, Scheer S, Dalit L, Groom JR, et al. The histone methyltransferase DOT1L is essential for Humoral immune responses. Cell Rep. 2020;33:108504.","journal-title":"Cell Rep"},{"key":"1464_CR74","doi-asserted-by":"publisher","first-page":"e00633","DOI":"10.7554\/eLife.00633","volume":"2","author":"MA Kerenyi","year":"2013","unstructured":"Kerenyi MA, Shao Z, Hsu YJ, Guo G, Luc S, O'Brien K, et al. Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife. 2013;2:e00633.","journal-title":"Elife"},{"key":"1464_CR75","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell. 2018;174:549\u2013563 e19.","journal-title":"Cell"},{"key":"1464_CR76","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41388-018-0451-5","volume":"38","author":"Y Qin","year":"2019","unstructured":"Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene. 2019;38:390\u2013405.","journal-title":"Oncogene"},{"key":"1464_CR77","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.tig.2004.02.007","volume":"20","author":"SJ Nowak","year":"2004","unstructured":"Nowak SJ, Corces VG. Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet. 2004;20:214\u201320.","journal-title":"Trends Genet"},{"key":"1464_CR78","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.4161\/epi.21975","volume":"7","author":"D Rossetto","year":"2012","unstructured":"Rossetto D, Avvakumov N, Cote J. Histone phosphorylation: a chromatin modification involved in diverse nuclear events. Epigenetics. 2012;7:1098\u2013108.","journal-title":"Epigenetics"},{"key":"1464_CR79","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1126\/science.1063127","volume":"293","author":"T Jenuwein","year":"2001","unstructured":"Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074\u201380.","journal-title":"Science"},{"key":"1464_CR80","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1101\/gr.176255.114","volume":"24","author":"A Sawicka","year":"2014","unstructured":"Sawicka A, Hartl D, Goiser M, Pusch O, Stocsits RR, Tamir IM, et al. H3S28 phosphorylation is a hallmark of the transcriptional response to cellular stress. Genome Res. 2014;24:1808\u201320.","journal-title":"Genome Res"},{"key":"1464_CR81","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.molcel.2016.09.026","volume":"64","author":"SZ Josefowicz","year":"2016","unstructured":"Josefowicz SZ, Shimada M, Armache A, Li CH, Miller RM, Lin S, et al. Chromatin kinases act on transcription factors and histone tails in regulation of inducible transcription. Mol Cell. 2016;64:347\u201361.","journal-title":"Mol Cell"},{"key":"1464_CR82","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41588-019-0428-5","volume":"51","author":"S Martire","year":"2019","unstructured":"Martire S, Gogate AA, Whitmill A, Tafessu A, Nguyen J, Teng YC, et al. Phosphorylation of histone H3.3 at serine 31 promotes p300 activity and enhancer acetylation. Nat Genet. 2019;51:941\u20136.","journal-title":"Nat Genet"},{"key":"1464_CR83","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41586-020-2533-0","volume":"583","author":"A Armache","year":"2020","unstructured":"Armache A, Yang S, Martinez de Paz A, Robbins LE, Durmaz C, Cheong JQ, et al. Histone H3.3 phosphorylation amplifies stimulation-induced transcription. Nature. 2020;583:852\u20137.","journal-title":"Nature"},{"key":"1464_CR84","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.molcel.2016.09.012","volume":"64","author":"H Aihara","year":"2016","unstructured":"Aihara H, Nakagawa T, Mizusaki H, Yoneda M, Kato M, Doiguchi M, et al. Histone H2A T120 phosphorylation promotes oncogenic transformation via upregulation of cyclin D1. Mol Cell. 2016;64:176\u201388.","journal-title":"Mol Cell"},{"key":"1464_CR85","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ccell.2017.05.003","volume":"31","author":"K Mahajan","year":"2017","unstructured":"Mahajan K, Malla P, Lawrence HR, Chen Z, Kumar-Sinha C, Malik R, et al. ACK1\/TNK2 regulates histone H4 Tyr88-phosphorylation and AR gene expression in castration-resistant prostate cancer. Cancer Cell. 2017;31:790\u2013803 e8.","journal-title":"Cancer Cell"},{"key":"1464_CR86","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1126\/science.1145801","volume":"318","author":"B Chang","year":"2007","unstructured":"Chang B, Chen Y, Zhao Y, Bruick RK. JMJD6 is a histone arginine demethylase. Science. 2007;318:444\u20137.","journal-title":"Science"},{"key":"1464_CR87","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1126\/science.1175865","volume":"325","author":"CJ Webby","year":"2009","unstructured":"Webby CJ, Wolf A, Gromak N, Dreger M, Kramer H, Kessler B, et al. Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science. 2009;325:90\u20133.","journal-title":"Science"},{"key":"1464_CR88","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/s41388-018-0466-y","volume":"38","author":"Y Liu","year":"2019","unstructured":"Liu Y, Long YH, Wang SQ, Zhang YY, Li YF, Mi JS, et al. JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity. Oncogene. 2019;38:980\u201397.","journal-title":"Oncogene"},{"key":"1464_CR89","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.molcel.2017.12.024","volume":"69","author":"L Wan","year":"2018","unstructured":"Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, et al. Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. Mol Cell. 2018;69:279\u2013291 e5.","journal-title":"Mol Cell"},{"key":"1464_CR90","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13148-019-0776-0","volume":"11","author":"A Ganesan","year":"2019","unstructured":"Ganesan A, Arimondo PB, Rots MG, Jeronimo C, Berdasco M. The timeline of epigenetic drug discovery: from reality to dreams. Clin Epigenetics. 2019;11:174.","journal-title":"Clin Epigenetics"},{"key":"1464_CR91","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","volume":"123","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123:8\u201313.","journal-title":"Int J Cancer"},{"key":"1464_CR92","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","volume":"26","author":"PA Marks","year":"2007","unstructured":"Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26:1351\u20136.","journal-title":"Oncogene"},{"key":"1464_CR93","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1517\/13543784.2011.594437","volume":"20","author":"EM Bertino","year":"2011","unstructured":"Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs. 2011;20:1151\u20138.","journal-title":"Expert Opin Investig Drugs"},{"key":"1464_CR94","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","volume":"138","author":"JJ McClure","year":"2018","unstructured":"McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:183\u2013211.","journal-title":"Adv Cancer Res"},{"key":"1464_CR95","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s40265-018-0978-3","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Ivosidenib: first global approval. Drugs. 2018;78:1509\u201316.","journal-title":"Drugs"},{"key":"1464_CR96","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41573-020-00108-x","volume":"20","author":"KP Bhat","year":"2021","unstructured":"Bhat KP, Umit Kaniskan H, Jin J, Gozani O. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021;20:265\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"1464_CR97","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1464_CR98","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1038\/onc.2008.271","volume":"27","author":"TL Whiteside","year":"2008","unstructured":"Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904\u201312.","journal-title":"Oncogene"},{"key":"1464_CR99","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","volume":"11","author":"A Labani-Motlagh","year":"2020","unstructured":"Labani-Motlagh A, Ashja-Mahdavi M, Loskog A. The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses. Front Immunol. 2020;11:940.","journal-title":"Front Immunol"},{"key":"1464_CR100","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174\u201386.","journal-title":"Nat Rev Cancer"},{"key":"1464_CR101","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4161\/epi.5.4.11684","volume":"5","author":"JA Watson","year":"2010","unstructured":"Watson JA, Watson CJ, McCann A, Baugh J. Epigenetics, the epicenter of the hypoxic response. Epigenetics. 2010;5:293\u20136.","journal-title":"Epigenetics"},{"key":"1464_CR102","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fcell.2019.00004","volume":"7","author":"W Al Tameemi","year":"2019","unstructured":"Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR. Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol. 2019;7:4.","journal-title":"Front Cell Dev Biol"},{"key":"1464_CR103","doi-asserted-by":"publisher","first-page":"36542","DOI":"10.1074\/jbc.M804578200","volume":"283","author":"S Beyer","year":"2008","unstructured":"Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem. 2008;283:36542\u201352.","journal-title":"J Biol Chem"},{"key":"1464_CR104","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1042\/BJ20081238","volume":"416","author":"PJ Pollard","year":"2008","unstructured":"Pollard PJ, Loenarz C, Mole DR, McDonough MA, Gleadle JM, Schofield CJ, et al. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J. 2008;416:387\u201394.","journal-title":"Biochem J"},{"key":"1464_CR105","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.bbrc.2008.05.150","volume":"372","author":"S Wellmann","year":"2008","unstructured":"Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK, et al. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun. 2008;372:892\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1464_CR106","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1128\/MCB.00444-09","volume":"30","author":"AJ Krieg","year":"2010","unstructured":"Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol. 2010;30:344\u201353.","journal-title":"Mol Cell Biol"},{"key":"1464_CR107","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.exphem.2011.08.004","volume":"39","author":"J Frikeche","year":"2011","unstructured":"Frikeche J, Clavert A, Delaunay J, Brissot E, Gregoire M, Gaugler B, et al. Impact of the hypomethylating agent 5-azacytidine on dendritic cells function. Exp Hematol. 2011;39:1056\u201363.","journal-title":"Exp Hematol"},{"key":"1464_CR108","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cyto.2010.11.002","volume":"53","author":"M Tausendschon","year":"2011","unstructured":"Tausendschon M, Dehne N, Brune B. Hypoxia causes epigenetic gene regulation in macrophages by attenuating Jumonji histone demethylase activity. Cytokine. 2011;53:256\u201362.","journal-title":"Cytokine"},{"key":"1464_CR109","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3390\/cancers12061411","volume":"12","author":"I Larionova","year":"2020","unstructured":"Larionova I, Kazakova E, Patysheva M, Kzhyshkowska J. Transcriptional, epigenetic and metabolic programming of tumor-associated macrophages. Cancers (Basel). 2020;12:1411.","journal-title":"Cancers (Basel)"},{"key":"1464_CR110","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.immuni.2017.04.016","volume":"46","author":"AT Phan","year":"2017","unstructured":"Phan AT, Goldrath AW, Glass CK. Metabolic and epigenetic coordination of T cell and macrophage immunity. Immunity. 2017;46:714\u201329.","journal-title":"Immunity"},{"key":"1464_CR111","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-immunol-093019-123619","volume":"39","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Cao X. Epigenetic remodeling in innate immunity and inflammation. Annu Rev Immunol. 2021;39:279\u2013311.","journal-title":"Annu Rev Immunol"},{"key":"1464_CR112","doi-asserted-by":"publisher","first-page":"651","DOI":"10.7150\/ijbs.7.651","volume":"7","author":"BF Zamarron","year":"2011","unstructured":"Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7:651\u20138.","journal-title":"Int J Biol Sci"},{"key":"1464_CR113","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1172\/JCI80007","volume":"125","author":"S Shalapour","year":"2015","unstructured":"Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125:3347\u201355.","journal-title":"J Clin Invest"},{"key":"1464_CR114","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3389\/fimmu.2018.00654","volume":"9","author":"B Cruickshank","year":"2018","unstructured":"Cruickshank B, Giacomantonio M, Marcato P, McFarland S, Pol J, Gujar S. Dying to be noticed: epigenetic regulation of immunogenic cell death for cancer immunotherapy. Front Immunol. 2018;9:654.","journal-title":"Front Immunol"},{"key":"1464_CR115","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41591-019-0499-y","volume":"25","author":"C Segovia","year":"2019","unstructured":"Segovia C, San Jose-Eneriz E, Munera-Maravilla E, Martinez-Fernandez M, Garate L, Miranda E, et al. Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression. Nat Med. 2019;25:1073\u201381.","journal-title":"Nat Med"},{"key":"1464_CR116","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/1078-0432.CCR-19-1351","volume":"26","author":"L Zhou","year":"2020","unstructured":"Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer. Clin Cancer Res. 2020;26:290\u2013300.","journal-title":"Clin Cancer Res"},{"key":"1464_CR117","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A. 2017;114:E10981\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1464_CR118","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","volume":"40","author":"X Li","year":"2021","unstructured":"Li X, Su X, Liu R, Pan Y, Fang J, Cao L, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021;40:1836\u201350.","journal-title":"Oncogene"},{"key":"1464_CR119","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep. 2018;23:3262\u201374.","journal-title":"Cell Rep"},{"key":"1464_CR120","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1172\/JCI99760","volume":"128","author":"S Goswami","year":"2018","unstructured":"Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018;128:3813\u20138.","journal-title":"J Clin Invest"},{"key":"1464_CR121","doi-asserted-by":"publisher","first-page":"948","DOI":"10.4161\/onci.20306","volume":"1","author":"L Shen","year":"2012","unstructured":"Shen L, Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology. 2012;1:948\u201350.","journal-title":"Oncoimmunology"},{"key":"1464_CR122","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, et al. Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020;10:723\u201333.","journal-title":"Acta Pharm Sin B"},{"key":"1464_CR123","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","volume":"33","author":"SR Woo","year":"2015","unstructured":"Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015;33:445\u201374.","journal-title":"Annu Rev Immunol"},{"key":"1464_CR124","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3389\/fimmu.2019.01119","volume":"10","author":"GM Boukhaled","year":"2019","unstructured":"Boukhaled GM, Corrado M, Guak H, Krawczyk CM. Chromatin architecture as an essential determinant of dendritic cell function. Front Immunol. 2019;10:1119.","journal-title":"Front Immunol"},{"key":"1464_CR125","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1073\/pnas.1814700116","volume":"116","author":"A Pacis","year":"2019","unstructured":"Pacis A, Mailhot-Leonard F, Tailleux L, Randolph HE, Yotova V, Dumaine A, et al. Gene activation precedes DNA demethylation in response to infection in human dendritic cells. Proc Natl Acad Sci U S A. 2019;116:6938\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1464_CR126","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13059-015-0863-2","volume":"17","author":"R Vento-Tormo","year":"2016","unstructured":"Vento-Tormo R, Company C, Rodriguez-Ubreva J, de la Rica L, Urquiza JM, Javierre BM, et al. IL-4 orchestrates STAT6-mediated DNA demethylation leading to dendritic cell differentiation. Genome Biol. 2016;17:4.","journal-title":"Genome Biol"},{"key":"1464_CR127","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4161\/epi.6.1.13314","volume":"6","author":"J Bullwinkel","year":"2011","unstructured":"Bullwinkel J, Ludemann A, Debarry J, Singh PB. Epigenotype switching at the CD14 and CD209 genes during differentiation of human monocytes to dendritic cells. Epigenetics. 2011;6:45\u201351.","journal-title":"Epigenetics"},{"key":"1464_CR128","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells9030561","volume":"9","author":"AMK Law","year":"2020","unstructured":"Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 2020;9:561.","journal-title":"Cells"},{"key":"1464_CR129","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.celrep.2017.09.018","volume":"21","author":"J Rodriguez-Ubreva","year":"2017","unstructured":"Rodriguez-Ubreva J, Catala-Moll F, Obermajer N, Alvarez-Errico D, Ramirez RN, Company C, et al. Prostaglandin E2 leads to the acquisition of DNMT3A-dependent tolerogenic functions in human myeloid-derived suppressor cells. Cell Rep. 2017;21:154\u201367.","journal-title":"Cell Rep"},{"key":"1464_CR130","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP Bottcher","year":"2018","unstructured":"Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172:1022\u20131037 e14.","journal-title":"Cell"},{"key":"1464_CR131","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1172\/JCI125916","volume":"129","author":"A Merino","year":"2019","unstructured":"Merino A, Zhang B, Dougherty P, Luo X, Wang J, Blazar BR, et al. Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming. J Clin Invest. 2019;129:3770\u201385.","journal-title":"J Clin Invest"},{"key":"1464_CR132","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/1878-0261.12443","volume":"13","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Chen H, Xie R, Wang H, Li S, Xu Q, et al. Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer. Mol Oncol. 2019;13:873\u201393.","journal-title":"Mol Oncol"},{"key":"1464_CR133","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.4049\/jimmunol.1100889","volume":"187","author":"M Heusinkveld","year":"2011","unstructured":"Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011;187:1157\u201365.","journal-title":"J Immunol"},{"key":"1464_CR134","doi-asserted-by":"publisher","first-page":"e1393596","DOI":"10.1080\/2162402X.2017.1393596","volume":"7","author":"S Borgoni","year":"2018","unstructured":"Borgoni S, Iannello A, Cutrupi S, Allavena P, D'Incalci M, Novelli F, et al. Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. Oncoimmunology. 2018;7:e1393596.","journal-title":"Oncoimmunology"},{"key":"1464_CR135","doi-asserted-by":"publisher","first-page":"57693","DOI":"10.18632\/oncotarget.17027","volume":"8","author":"D Zhou","year":"2017","unstructured":"Zhou D, Yang K, Chen L, Zhang W, Xu Z, Zuo J, et al. Promising landscape for regulating macrophage polarization: epigenetic viewpoint. Oncotarget. 2017;8:57693\u2013706.","journal-title":"Oncotarget"},{"key":"1464_CR136","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41423-019-0315-0","volume":"17","author":"S Chen","year":"2020","unstructured":"Chen S, Yang J, Wei Y, Wei X. Epigenetic regulation of macrophages: from homeostasis maintenance to host defense. Cell Mol Immunol. 2020;17:36\u201349.","journal-title":"Cell Mol Immunol"},{"key":"1464_CR137","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.celrep.2018.06.040","volume":"24","author":"A Nguyen","year":"2018","unstructured":"Nguyen A, Ho L, Workenhe ST, Chen L, Samson J, Walsh SR, et al. HDACi delivery reprograms tumor-infiltrating myeloid cells to eliminate antigen-loss variants. Cell Rep. 2018;24:642\u201354.","journal-title":"Cell Rep"},{"key":"1464_CR138","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.molimm.2014.08.002","volume":"63","author":"E Sahakian","year":"2015","unstructured":"Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, et al. Histone deacetylase 11: a novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol. 2015;63:579\u201385.","journal-title":"Mol Immunol"},{"key":"1464_CR139","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.4049\/jimmunol.1601712","volume":"198","author":"J Xin","year":"2017","unstructured":"Xin J, Zhang Z, Su X, Wang L, Zhang Y, Yang R. Epigenetic component p66a modulates myeloid-derived suppressor cells by modifying STAT3. J Immunol. 2017;198:2712\u201320.","journal-title":"J Immunol"},{"key":"1464_CR140","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-18-2395","volume":"79","author":"S Huang","year":"2019","unstructured":"Huang S, Wang Z, Zhou J, Huang J, Zhou L, Luo J, et al. EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells. Cancer Res. 2019;79:2009\u201320.","journal-title":"Cancer Res"},{"key":"1464_CR141","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1189\/jlb.0311119","volume":"91","author":"BR Rosborough","year":"2012","unstructured":"Rosborough BR, Castellaneta A, Natarajan S, Thomson AW, Turnquist HR. Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol. 2012;91:701\u20139.","journal-title":"J Leukoc Biol"},{"key":"1464_CR142","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00262-016-1935-1","volume":"66","author":"HF Wang","year":"2017","unstructured":"Wang HF, Ning F, Liu ZC, Wu L, Li ZQ, Qi YF, et al. Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro. Cancer Immunol Immunother. 2017;66:355\u201366.","journal-title":"Cancer Immunol Immunother"},{"key":"1464_CR143","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.7150\/jca.44622","volume":"11","author":"YD Kim","year":"2020","unstructured":"Kim YD, Park SM, Ha HC, Lee AR, Won H, Cha H, et al. HDAC inhibitor, CG-745, enhances the anti-cancer effect of anti-PD-1 immune checkpoint inhibitor by modulation of the immune microenvironment. J Cancer. 2020;11:4059\u201372.","journal-title":"J Cancer"},{"key":"1464_CR144","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.celrep.2016.03.035","volume":"15","author":"D Zhao","year":"2016","unstructured":"Zhao D, Zhang Q, Liu Y, Li X, Zhao K, Ding Y, et al. H3K4me3 demethylase Kdm5a is required for NK cell activation by associating with p50 to suppress SOCS1. Cell Rep. 2016;15:288\u201399.","journal-title":"Cell Rep"},{"key":"1464_CR145","doi-asserted-by":"publisher","first-page":"eaba6232","DOI":"10.1126\/sciimmunol.aba6232","volume":"5","author":"V Stary","year":"2020","unstructured":"Stary V, Pandey RV, Strobl J, Kleissl L, Starlinger P, Pereyra D, et al. A discrete subset of epigenetically primed human NK cells mediates antigen-specific immune responses. Sci Immunol. 2020;5:eaba6232.","journal-title":"Sci Immunol"},{"key":"1464_CR146","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","volume":"38","author":"M Ruterbusch","year":"2020","unstructured":"Ruterbusch M, Pruner KB, Shehata L, Pepper M. In vivo CD4(+) T cell differentiation and function: revisiting the Th1\/Th2 paradigm. Annu Rev Immunol. 2020;38:705\u201325.","journal-title":"Annu Rev Immunol"},{"key":"1464_CR147","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/383787a0","volume":"383","author":"AK Abbas","year":"1996","unstructured":"Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787\u201393.","journal-title":"Nature"},{"key":"1464_CR148","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485\u2013517.","journal-title":"Annu Rev Immunol"},{"key":"1464_CR149","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.immuni.2006.03.007","volume":"24","author":"GR Lee","year":"2006","unstructured":"Lee GR, Kim ST, Spilianakis CG, Fields PE, Flavell RA. T helper cell differentiation: regulation by cis elements and epigenetics. Immunity. 2006;24:369\u201379.","journal-title":"Immunity"},{"key":"1464_CR150","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.immuni.2010.06.003","volume":"32","author":"L Wei","year":"2010","unstructured":"Wei L, Vahedi G, Sun HW, Watford WT, Takatori H, Ramos HL, et al. Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. Immunity. 2010;32:840\u201351.","journal-title":"Immunity"},{"key":"1464_CR151","doi-asserted-by":"publisher","first-page":"31470","DOI":"10.1074\/jbc.M504766200","volume":"280","author":"M Koyanagi","year":"2005","unstructured":"Koyanagi M, Baguet A, Martens J, Margueron R, Jenuwein T, Bix M. EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene silencing in Th1 cells. J Biol Chem. 2005;280:31470\u20137.","journal-title":"J Biol Chem"},{"key":"1464_CR152","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.3389\/fimmu.2018.02929","volume":"9","author":"A Onodera","year":"2018","unstructured":"Onodera A, Kokubo K, Nakayama T. Epigenetic and transcriptional regulation in the induction, maintenance, heterogeneity, and recall-response of effector and memory Th2 cells. Front Immunol. 2018;9:2929.","journal-title":"Front Immunol"},{"key":"1464_CR153","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2012.01.056","volume":"149","author":"JA Zhang","year":"2012","unstructured":"Zhang JA, Mortazavi A, Williams BA, Wold BJ, Rothenberg EV. Dynamic transformations of genome-wide epigenetic marking and transcriptional control establish T cell identity. Cell. 2012;149:467\u201382.","journal-title":"Cell"},{"key":"1464_CR154","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ni.1659","volume":"9","author":"M Veldhoen","year":"2008","unstructured":"Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-beta \u2018reprograms\u2019 the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008;9:1341\u20136.","journal-title":"Nat Immunol"},{"key":"1464_CR155","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1038\/s41467-021-23042-x","volume":"12","author":"S Roy","year":"2021","unstructured":"Roy S, Rizvi ZA, Clarke AJ, Macdonald F, Pandey A, Zaiss DMW, et al. EGFR-HIF1alpha signaling positively regulates the differentiation of IL-9 producing T helper cells. Nat Commun. 2021;12:3182.","journal-title":"Nat Commun"},{"key":"1464_CR156","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.immuni.2016.05.009","volume":"44","author":"Y Wang","year":"2016","unstructured":"Wang Y, Bi Y, Chen X, Li C, Li Y, Zhang Z, et al. Histone deacetylase SIRT1 negatively regulates the differentiation of interleukin-9-producing CD4(+) T cells. Immunity. 2016;44:1337\u201349.","journal-title":"Immunity"},{"key":"1464_CR157","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.4049\/jimmunol.1300433","volume":"191","author":"A Wang","year":"2013","unstructured":"Wang A, Pan D, Lee YH, Martinez GJ, Feng XH, Dong C. Cutting edge: Smad2 and Smad4 regulate TGF-beta-mediated Il9 gene expression via EZH2 displacement. J Immunol. 2013;191:4908\u201312.","journal-title":"J Immunol"},{"key":"1464_CR158","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1182\/blood-2011-11-392589","volume":"119","author":"A Ramming","year":"2012","unstructured":"Ramming A, Druzd D, Leipe J, Schulze-Koops H, Skapenko A. Maturation-related histone modifications in the PU.1 promoter regulate Th9-cell development. Blood. 2012;119:4665\u201374.","journal-title":"Blood"},{"key":"1464_CR159","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.1074\/jbc.C600322200","volume":"282","author":"AM Akimzhanov","year":"2007","unstructured":"Akimzhanov AM, Yang XO, Dong C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. J Biol Chem. 2007;282:5969\u201372.","journal-title":"J Biol Chem"},{"key":"1464_CR160","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/ijms21051673","volume":"21","author":"E Renaude","year":"2020","unstructured":"Renaude E, Kroemer M, Loyon R, Binda D, Borg C, Guittaut M, et al. The fate of Th17 cells is shaped by epigenetic modifications and remodeled by the tumor microenvironment. Int J Mol Sci. 2020;21:1673.","journal-title":"Int J Mol Sci"},{"key":"1464_CR161","doi-asserted-by":"publisher","first-page":"e002603","DOI":"10.1136\/jitc-2021-002603","volume":"9","author":"BS Kim","year":"2021","unstructured":"Kim BS, Kuen DS, Koh CH, Kim HD, Chang SH, Kim S, et al. Type 17 immunity promotes the exhaustion of CD8(+) T cells in cancer. J Immunother Cancer. 2021;9:e002603.","journal-title":"J Immunother Cancer"},{"key":"1464_CR162","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1084\/jem.20190337","volume":"216","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Zhao Y, Zou L, Zhang D, Aki D, Liu YC. The E3 ligase VHL promotes follicular helper T cell differentiation via glycolytic-epigenetic control. J Exp Med. 2019;216:1664\u201381.","journal-title":"J Exp Med"},{"key":"1464_CR163","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1038\/s41467-018-07853-z","volume":"9","author":"F Li","year":"2018","unstructured":"Li F, Zeng Z, Xing S, Gullicksrud JA, Shan Q, Choi J, et al. Ezh2 programs TFH differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf. Nat Commun. 2018;9:5452.","journal-title":"Nat Commun"},{"key":"1464_CR164","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057\u201361.","journal-title":"Science"},{"key":"1464_CR165","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330\u20136.","journal-title":"Nat Immunol"},{"key":"1464_CR166","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nature05543","volume":"445","author":"MA Gavin","year":"2007","unstructured":"Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007;445:771\u20135.","journal-title":"Nature"},{"key":"1464_CR167","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1371\/journal.pbio.0050038","volume":"5","author":"S Floess","year":"2007","unstructured":"Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5:e38.","journal-title":"PLoS Biol"},{"key":"1464_CR168","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4049\/jimmunol.182.1.259","volume":"182","author":"G Lal","year":"2009","unstructured":"Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 2009;182:259\u201373.","journal-title":"J Immunol"},{"key":"1464_CR169","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1182\/blood-2009-05-219584","volume":"114","author":"G Lal","year":"2009","unstructured":"Lal G, Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood. 2009;114:3727\u201335.","journal-title":"Blood"},{"key":"1464_CR170","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1038\/s41598-020-63572-w","volume":"10","author":"L Kouakanou","year":"2020","unstructured":"Kouakanou L, Peters C, Sun Q, Floess S, Bhat J, Huehn J, et al. Vitamin C supports conversion of human gammadelta T cells into FOXP3-expressing regulatory cells by epigenetic regulation. Sci Rep. 2020;10:6550.","journal-title":"Sci Rep"},{"key":"1464_CR171","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1084\/jem.20151438","volume":"213","author":"X Yue","year":"2016","unstructured":"Yue X, Trifari S, Aijo T, Tsagaratou A, Pastor WA, Zepeda-Martinez JA, et al. Control of Foxp3 stability through modulation of TET activity. J Exp Med. 2016;213:377\u201397.","journal-title":"J Exp Med"},{"key":"1464_CR172","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/s41467-019-09541-y","volume":"10","author":"X Yue","year":"2019","unstructured":"Yue X, Lio CJ, Samaniego-Castruita D, Li X, Rao A. Loss of TET2 and TET3 in regulatory T cells unleashes effector function. Nat Commun. 2019;10:2011.","journal-title":"Nat Commun"},{"key":"1464_CR173","doi-asserted-by":"publisher","first-page":"e52716","DOI":"10.15252\/embr.202152716","volume":"22","author":"X Yue","year":"2021","unstructured":"Yue X, Samaniego-Castruita D, Gonzalez-Avalos E, Li X, Barwick BG, Rao A. Whole-genome analysis of TET dioxygenase function in regulatory T cells. EMBO Rep. 2021;22:e52716.","journal-title":"EMBO Rep"},{"key":"1464_CR174","doi-asserted-by":"publisher","first-page":"10643","DOI":"10.1038\/srep10643","volume":"5","author":"XP Yang","year":"2015","unstructured":"Yang XP, Jiang K, Hirahara K, Vahedi G, Afzali B, Sciume G, et al. EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion. Sci Rep. 2015;5:10643.","journal-title":"Sci Rep"},{"key":"1464_CR175","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.immuni.2015.01.007","volume":"42","author":"M DuPage","year":"2015","unstructured":"DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity. 2015;42:227\u201338.","journal-title":"Immunity"},{"key":"1464_CR176","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.jid.2018.12.024","volume":"139","author":"N Nikbakht","year":"2019","unstructured":"Nikbakht N, Tiago M, Erkes DA, Chervoneva I, Aplin AE. BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade. J Invest Dermatol. 2019;139:1612\u20135.","journal-title":"J Invest Dermatol"},{"key":"1464_CR177","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/iub.351","volume":"62","author":"MR Olson","year":"2010","unstructured":"Olson MR, Russ BE, Doherty PC, Turner SJ. The role of epigenetics in the acquisition and maintenance of effector function in virus-specific CD8 T cells. IUBMB Life. 2010;62:519\u201326.","journal-title":"IUBMB Life"},{"key":"1464_CR178","doi-asserted-by":"publisher","first-page":"8102","DOI":"10.4049\/jimmunol.180.12.8102","volume":"180","author":"Y Araki","year":"2008","unstructured":"Araki Y, Fann M, Wersto R, Weng NP. Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B). J Immunol. 2008;180:8102\u20138.","journal-title":"J Immunol"},{"key":"1464_CR179","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.aah6499","volume":"359","author":"L Pace","year":"2018","unstructured":"Pace L, Goudot C, Zueva E, Gueguen P, Burgdorf N, Waterfall JJ, et al. The epigenetic control of stemness in CD8(+) T cell fate commitment. Science. 2018;359:177\u201386.","journal-title":"Science"},{"key":"1464_CR180","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/ni.3706","volume":"18","author":"B Yu","year":"2017","unstructured":"Yu B, Zhang K, Milner JJ, Toma C, Chen R, Scott-Browne JP, et al. Epigenetic landscapes reveal transcription factors that regulate CD8(+) T cell differentiation. Nat Immunol. 2017;18:573\u201382.","journal-title":"Nat Immunol"},{"key":"1464_CR181","doi-asserted-by":"publisher","first-page":"865","DOI":"10.4049\/jimmunol.181.2.865","volume":"181","author":"JK Northrop","year":"2008","unstructured":"Northrop JK, Wells AD, Shen H. Cutting edge: chromatin remodeling as a molecular basis for the enhanced functionality of memory CD8 T cells. J Immunol. 2008;181:865\u20138.","journal-title":"J Immunol"},{"key":"1464_CR182","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2009.05.006","volume":"30","author":"Y Araki","year":"2009","unstructured":"Araki Y, Wang Z, Zang C, Wood WH 3rd, Schones D, Cui K, et al. Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells. Immunity. 2009;30:912\u201325.","journal-title":"Immunity"},{"key":"1464_CR183","doi-asserted-by":"publisher","first-page":"201703","DOI":"10.1155\/2015\/201703","volume":"2015","author":"R Yasmin","year":"2015","unstructured":"Yasmin R, Siraj S, Hassan A, Khan AR, Abbasi R, Ahmad N. Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies. Mediat Inflamm. 2015;2015:201703.","journal-title":"Mediat Inflamm"},{"key":"1464_CR184","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.4049\/jimmunol.0901522","volume":"183","author":"T Juelich","year":"2009","unstructured":"Juelich T, Sutcliffe EL, Denton A, He Y, Doherty PC, Parish CR, et al. Interplay between chromatin remodeling and epigenetic changes during lineage-specific commitment to granzyme B expression. J Immunol. 2009;183:7063\u201372.","journal-title":"J Immunol"},{"key":"1464_CR185","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ni887","volume":"4","author":"D Bruniquel","year":"2003","unstructured":"Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol. 2003;4:235\u201340.","journal-title":"Nat Immunol"},{"key":"1464_CR186","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/sj.emboj.7601012","volume":"25","author":"A Murayama","year":"2006","unstructured":"Murayama A, Sakura K, Nakama M, Yasuzawa-Tanaka K, Fujita E, Tateishi Y, et al. A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. EMBO J. 2006;25:1081\u201392.","journal-title":"EMBO J"},{"key":"1464_CR187","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.4049\/jimmunol.177.2.1062","volume":"177","author":"JK Northrop","year":"2006","unstructured":"Northrop JK, Thomas RM, Wells AD, Shen H. Epigenetic remodeling of the IL-2 and IFN-gamma loci in memory CD8 T cells is influenced by CD4 T cells. J Immunol. 2006;177:1062\u20139.","journal-title":"J Immunol"},{"key":"1464_CR188","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1182\/blood-2007-08-106443","volume":"111","author":"H Wen","year":"2008","unstructured":"Wen H, Dou Y, Hogaboam CM, Kunkel SL. Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood. 2008;111:1797\u2013804.","journal-title":"Blood"},{"key":"1464_CR189","doi-asserted-by":"publisher","first-page":"e2013598118","DOI":"10.1073\/pnas.2013598118","volume":"118","author":"R Falahat","year":"2021","unstructured":"Falahat R, Berglund A, Putney RM, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, et al. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc Natl Acad Sci U S A. 2021;118:e2013598118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1464_CR190","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359\u201370.","journal-title":"Mol Cell"},{"key":"1464_CR191","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13148-018-0512-1","volume":"10","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, El Salhat H, Taha RZ, John A, Ali BR, Elkord E. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. Clin Epigenetics. 2018;10:78.","journal-title":"Clin Epigenetics"},{"key":"1464_CR192","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13148-018-0539-3","volume":"10","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, Toor SM, Taha RZ, Shaath H, Elkord E. DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clin Epigenetics. 2018;10:104.","journal-title":"Clin Epigenetics"},{"key":"1464_CR193","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17:1142\u20139.","journal-title":"Nat Immunol"},{"key":"1464_CR194","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","volume":"18","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18:152.","journal-title":"Mol Cancer"},{"key":"1464_CR195","doi-asserted-by":"publisher","first-page":"690105","DOI":"10.3389\/fimmu.2021.690105","volume":"12","author":"JN Filderman","year":"2021","unstructured":"Filderman JN, Appleman M, Chelvanambi M, Taylor JL, Storkus WJ. STINGing the tumor microenvironment to promote therapeutic tertiary lymphoid structure development. Front Immunol. 2021;12:690105.","journal-title":"Front Immunol"},{"key":"1464_CR196","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41388-017-0120-0","volume":"37","author":"H Konno","year":"2018","unstructured":"Konno H, Yamauchi S, Berglund A, Putney RM, Mule JJ, Barber GN. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene. 2018;37:2037\u201351.","journal-title":"Oncogene"},{"key":"1464_CR197","doi-asserted-by":"publisher","first-page":"e2006134","DOI":"10.1371\/journal.pbio.2006134","volume":"16","author":"L Wu","year":"2018","unstructured":"Wu L, Cao J, Cai WL, Lang SM, Horton JR, Jansen DJ, et al. KDM5 histone demethylases repress immune response via suppression of STING. PLoS Biol. 2018;16:e2006134.","journal-title":"PLoS Biol"},{"key":"1464_CR198","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","volume":"9","author":"S Kitajima","year":"2019","unstructured":"Kitajima S, Ivanova E, Guo S, Yoshida R, Campisi M, Sundararaman SK, et al. Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer. Cancer Discov. 2019;9:34\u201345.","journal-title":"Cancer Discov"},{"key":"1464_CR199","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1084\/jem.188.1.103","volume":"188","author":"DR Fitzpatrick","year":"1998","unstructured":"Fitzpatrick DR, Shirley KM, McDonald LE, Bielefeldt-Ohmann H, Kay GF, Kelso A. Distinct methylation of the interferon gamma (IFN-gamma) and interleukin 3 (IL-3) genes in newly activated primary CD8+ T lymphocytes: regional IFN-gamma promoter demethylation and mRNA expression are heritable in CD44(high)CD8+ T cells. J Exp Med. 1998;188:103\u201317.","journal-title":"J Exp Med"},{"key":"1464_CR200","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.4049\/jimmunol.176.7.4083","volume":"176","author":"EN Kersh","year":"2006","unstructured":"Kersh EN, Fitzpatrick DR, Murali-Krishna K, Shires J, Speck SH, Boss JM, et al. Rapid demethylation of the IFN-gamma gene occurs in memory but not naive CD8 T cells. J Immunol. 2006;176:4083\u201393.","journal-title":"J Immunol"},{"key":"1464_CR201","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.4049\/jimmunol.174.8.4639","volume":"174","author":"RM Thomas","year":"2005","unstructured":"Thomas RM, Gao L, Wells AD. Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J Immunol. 2005;174:4639\u201346.","journal-title":"J Immunol"},{"key":"1464_CR202","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1128\/MCB.25.8.3209-3219.2005","volume":"25","author":"X Chen","year":"2005","unstructured":"Chen X, Wang J, Woltring D, Gerondakis S, Shannon MF. Histone dynamics on the interleukin-2 gene in response to T-cell activation. Mol Cell Biol. 2005;25:3209\u201319.","journal-title":"Mol Cell Biol"},{"key":"1464_CR203","doi-asserted-by":"publisher","first-page":"35456","DOI":"10.1074\/jbc.M111.236794","volume":"286","author":"Y Wakabayashi","year":"2011","unstructured":"Wakabayashi Y, Tamiya T, Takada I, Fukaya T, Sugiyama Y, Inoue N, et al. Histone 3 lysine 9 (H3K9) methyltransferase recruitment to the interleukin-2 (IL-2) promoter is a mechanism of suppression of IL-2 transcription by the transforming growth factor-beta-Smad pathway. J Biol Chem. 2011;286:35456\u201365.","journal-title":"J Biol Chem"},{"key":"1464_CR204","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1038\/s41467-018-07806-6","volume":"9","author":"L Chorro","year":"2018","unstructured":"Chorro L, Suzuki M, Chin SS, Williams TM, Snapp EL, Odagiu L, et al. Interleukin 2 modulates thymic-derived regulatory T cell epigenetic landscape. Nat Commun. 2018;9:5368.","journal-title":"Nat Commun"},{"key":"1464_CR205","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1158\/0008-5472.CAN-04-1261","volume":"64","author":"RB Mailliard","year":"2004","unstructured":"Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934\u20137.","journal-title":"Cancer Res"},{"key":"1464_CR206","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958\u201369.","journal-title":"Nat Rev Immunol"},{"key":"1464_CR207","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","volume":"34","author":"SH Baumeister","year":"2016","unstructured":"Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539\u201373.","journal-title":"Annu Rev Immunol"},{"key":"1464_CR208","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3389\/fimmu.2020.01469","volume":"11","author":"R Saleh","year":"2020","unstructured":"Saleh R, Toor SM, Sasidharan Nair V, Elkord E. Role of epigenetic modifications in inhibitory immune checkpoints in cancer development and progression. Front Immunol. 2020;11:1469.","journal-title":"Front Immunol"},{"key":"1464_CR209","doi-asserted-by":"publisher","first-page":"e002949","DOI":"10.1136\/jitc-2020-000552","volume":"8","author":"N Klumper","year":"2020","unstructured":"Klumper N, Ralser DJ, Bawden EG, Landsberg J, Zarbl R, Kristiansen G, et al. LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma. J Immunother Cancer. 2020;8:e002949.","journal-title":"J Immunother Cancer"},{"key":"1464_CR210","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280\u20138.","journal-title":"Leukemia"},{"key":"1464_CR211","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","volume":"3","author":"DM Woods","year":"2015","unstructured":"Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res. 2015;3:1375\u201385.","journal-title":"Cancer Immunol Res"},{"key":"1464_CR212","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13148-017-0354-2","volume":"9","author":"S Marwitz","year":"2017","unstructured":"Marwitz S, Scheufele S, Perner S, Reck M, Ammerpohl O, Goldmann T. Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression. Clin Epigenetics. 2017;9:51.","journal-title":"Clin Epigenetics"},{"key":"1464_CR213","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41423-020-0505-9","volume":"17","author":"X Pan","year":"2020","unstructured":"Pan X, Zheng L. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. Cell Mol Immunol. 2020;17:940\u201353.","journal-title":"Cell Mol Immunol"},{"key":"1464_CR214","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018;128:580\u20138.","journal-title":"J Clin Invest"},{"key":"1464_CR215","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"PS Ward","year":"2012","unstructured":"Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21:297\u2013308.","journal-title":"Cancer Cell"},{"key":"1464_CR216","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","volume":"3","author":"I Elia","year":"2021","unstructured":"Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3:21\u201332.","journal-title":"Nat Metab"},{"key":"1464_CR217","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nrc.2016.82","volume":"16","author":"A Kinnaird","year":"2016","unstructured":"Kinnaird A, Zhao S, Wellen KE, Michelakis ED. Metabolic control of epigenetics in cancer. Nat Rev Cancer. 2016;16:694\u2013707.","journal-title":"Nat Rev Cancer"},{"key":"1464_CR218","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/cr.2015.68","volume":"25","author":"B Kelly","year":"2015","unstructured":"Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25:771\u201384.","journal-title":"Cell Res"},{"key":"1464_CR219","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/ni.3796","volume":"18","author":"PS Liu","year":"2017","unstructured":"Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, et al. alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18:985\u201394.","journal-title":"Nat Immunol"},{"key":"1464_CR220","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1084\/jem.20181211","volume":"215","author":"W Zhang","year":"2018","unstructured":"Zhang W, Li Q, Li D, Li J, Aki D, Liu YC. The E3 ligase VHL controls alveolar macrophage function via metabolic-epigenetic regulation. J Exp Med. 2018;215:3180\u201393.","journal-title":"J Exp Med"},{"key":"1464_CR221","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1172\/JCI69589","volume":"123","author":"M Sukumar","year":"2013","unstructured":"Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest. 2013;123:4479\u201388.","journal-title":"J Clin Invest"},{"key":"1464_CR222","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1073\/pnas.1920413117","volume":"117","author":"D Hermans","year":"2020","unstructured":"Hermans D, Gautam S, Garcia-Canaveras JC, Gromer D, Mitra S, Spolski R, et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8(+) T cell stemness and antitumor immunity. Proc Natl Acad Sci U S A. 2020;117:6047\u201355.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1464_CR223","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","volume":"26","author":"RJ Kishton","year":"2017","unstructured":"Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab. 2017;26:94\u2013109.","journal-title":"Cell Metab"},{"key":"1464_CR224","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco F, Jaccard A, Romero P, Yu YR, Ho PC. Metabolic and epigenetic regulation of T-cell exhaustion. Nat Metab. 2020;2:1001\u201312.","journal-title":"Nat Metab"},{"key":"1464_CR225","doi-asserted-by":"publisher","first-page":"640369","DOI":"10.3389\/fimmu.2021.640369","volume":"12","author":"Y Yang","year":"2021","unstructured":"Yang Y, Wang Y. Role of epigenetic regulation in plasticity of tumor immune microenvironment. Front Immunol. 2021;12:640369.","journal-title":"Front Immunol"},{"key":"1464_CR226","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.tips.2010.08.001","volume":"31","author":"X Yang","year":"2010","unstructured":"Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci. 2010;31:536\u201346.","journal-title":"Trends Pharmacol Sci"},{"key":"1464_CR227","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97\u2013111.","journal-title":"Nat Rev Immunol"},{"key":"1464_CR228","doi-asserted-by":"publisher","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","volume":"3","author":"O Kepp","year":"2014","unstructured":"Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691.","journal-title":"Oncoimmunology"},{"key":"1464_CR229","doi-asserted-by":"publisher","first-page":"e000195","DOI":"10.1136\/jitc-2019-000195","volume":"8","author":"J Laengle","year":"2020","unstructured":"Laengle J, Kabiljo J, Hunter L, Homola J, Prodinger S, Egger G, et al. Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis. J Immunother Cancer. 2020;8:e000195.","journal-title":"J Immunother Cancer"},{"key":"1464_CR230","doi-asserted-by":"publisher","first-page":"26361","DOI":"10.18632\/oncotarget.8379","volume":"7","author":"M Buoncervello","year":"2016","unstructured":"Buoncervello M, Romagnoli G, Buccarelli M, Fragale A, Toschi E, Parlato S, et al. IFN-alpha potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget. 2016;7:26361\u201373.","journal-title":"Oncotarget"},{"key":"1464_CR231","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1158\/2326-6066.CIR-17-0080","volume":"5","author":"A Fragale","year":"2017","unstructured":"Fragale A, Romagnoli G, Licursi V, Buoncervello M, Del Vecchio G, Giuliani C, et al. Antitumor effects of Epidrug\/IFNalpha combination driven by modulated gene signatures in both colorectal cancer and dendritic cells. Cancer Immunol Res. 2017;5:604\u201316.","journal-title":"Cancer Immunol Res"},{"key":"1464_CR232","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/nm1652","volume":"13","author":"R Tao","year":"2007","unstructured":"Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13:1299\u2013307.","journal-title":"Nat Med"},{"key":"1464_CR233","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2010-05-284711","volume":"117","author":"T Roger","year":"2010","unstructured":"Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T, et al. Histone deacetylase inhibitors impair innate immune responses to toll-like receptor agonists and to infection. Blood. 2010;117:1205\u201317.","journal-title":"Blood"},{"key":"1464_CR234","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/nrd3031","volume":"8","author":"L Wang","year":"2009","unstructured":"Wang L, de Zoeten EF, Greene MI, Hancock WW. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov. 2009;8:969\u201381.","journal-title":"Nat Rev Drug Discov"},{"key":"1464_CR235","doi-asserted-by":"publisher","first-page":"e30815","DOI":"10.1371\/journal.pone.0030815","volume":"7","author":"L Shen","year":"2012","unstructured":"Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One. 2012;7:e30815.","journal-title":"PLoS One"},{"key":"1464_CR236","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4103\/jcrt.JCRT_986_19","volume":"16","author":"W Sun","year":"2020","unstructured":"Sun W, Chen L, Tang J, Zhang C, Wen Y, Wen W. Targeting EZH2 depletes LMP1-induced activated regulatory T cells enhancing antitumor immunity in nasopharyngeal carcinoma. J Cancer Res Ther. 2020;16:309\u201319.","journal-title":"J Cancer Res Ther"},{"key":"1464_CR237","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.celrep.2019.03.008","volume":"27","author":"DE de Almeida Nagata","year":"2019","unstructured":"de Almeida Nagata DE, Chiang EY, Jhunjhunwala S, Caplazi P, Arumugam V, Modrusan Z, et al. Regulation of tumor-associated myeloid cell activity by CBP\/EP300 bromodomain modulation of H3K27 acetylation. Cell Rep. 2019;27:269\u2013281 e4.","journal-title":"Cell Rep"},{"key":"1464_CR238","doi-asserted-by":"publisher","first-page":"20908","DOI":"10.18632\/oncotarget.24556","volume":"9","author":"AE de Groot","year":"2018","unstructured":"de Groot AE, Pienta KJ. Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget. 2018;9:20908\u201327.","journal-title":"Oncotarget"},{"key":"1464_CR239","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41422-020-0379-5","volume":"30","author":"JA Shyer","year":"2020","unstructured":"Shyer JA, Flavell RA, Bailis W. Metabolic signaling in T cells. Cell Res. 2020;30:649\u201359.","journal-title":"Cell Res"},{"key":"1464_CR240","doi-asserted-by":"publisher","first-page":"645242","DOI":"10.3389\/fimmu.2021.645242","volume":"12","author":"GO Rangel Rivera","year":"2021","unstructured":"Rangel Rivera GO, Knochelmann HM, Dwyer CJ, Smith AS, Wyatt MM, Rivera-Reyes AM, et al. Fundamentals of T cell metabolism and strategies to enhance cancer immunotherapy. Front Immunol. 2021;12:645242.","journal-title":"Front Immunol"},{"key":"1464_CR241","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-020-2682-1","volume":"585","author":"Y Bian","year":"2020","unstructured":"Bian Y, Li W, Kremer DM, Sajjakulnukit P, Li S, Crespo J, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585:277\u201382.","journal-title":"Nature"},{"key":"1464_CR242","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.it.2020.06.008","volume":"41","author":"CC Zebley","year":"2020","unstructured":"Zebley CC, Gottschalk S, Youngblood B. Rewriting history: epigenetic reprogramming of CD8(+) T cell differentiation to enhance immunotherapy. Trends Immunol. 2020;41:665\u201375.","journal-title":"Trends Immunol"},{"key":"1464_CR243","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tong C, Dai H, Wu Z, Han X, Guo Y, et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun. 2021;12:409.","journal-title":"Nat Commun"},{"key":"1464_CR244","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1183\/09031936.00081310","volume":"38","author":"S Leclercq","year":"2011","unstructured":"Leclercq S, Gueugnon F, Boutin B, Guillot F, Blanquart C, Rogel A, et al. A 5-aza-2\u2032-deoxycytidine\/valproate combination induces cytotoxic T-cell response against mesothelioma. Eur Respir J. 2011;38:1105\u201316.","journal-title":"Eur Respir J"},{"key":"1464_CR245","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/0952-7915(94)90075-2","volume":"6","author":"S Ostrand-Rosenberg","year":"1994","unstructured":"Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol. 1994;6:722\u20137.","journal-title":"Curr Opin Immunol"},{"key":"1464_CR246","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejca.2016.09.010","volume":"68","author":"M de Charette","year":"2016","unstructured":"de Charette M, Marabelle A, Houot R. Turning tumour cells into antigen presenting cells: the next step to improve cancer immunotherapy? Eur J Cancer. 2016;68:134\u201347.","journal-title":"Eur J Cancer"},{"key":"1464_CR247","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1172\/JCI131234","volume":"130","author":"A Berglund","year":"2020","unstructured":"Berglund A, Mills M, Putney RM, Hamaidi I, Mule J, Kim S. Methylation of immune synapse genes modulates tumor immunogenicity. J Clin Invest. 2020;130:974\u201380.","journal-title":"J Clin Invest"},{"key":"1464_CR248","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00262-007-0402-4","volume":"57","author":"AN Khan","year":"2008","unstructured":"Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother. 2008;57:647\u201354.","journal-title":"Cancer Immunol Immunother"},{"key":"1464_CR249","doi-asserted-by":"publisher","first-page":"9601","DOI":"10.1158\/0008-5472.CAN-07-5270","volume":"68","author":"AF Setiadi","year":"2008","unstructured":"Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 2008;68:9601\u20137.","journal-title":"Cancer Res"},{"key":"1464_CR250","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fonc.2014.00074","volume":"4","author":"ZS Guo","year":"2014","unstructured":"Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014;4:74.","journal-title":"Front Oncol"},{"key":"1464_CR251","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1158\/1535-7163.MCT-20-0377","volume":"20","author":"L Scotto","year":"2021","unstructured":"Scotto L, Kinahan C, Douglass E, Deng C, Safari M, Casadei B, et al. Targeting the T-cell lymphoma epigenome induces cell death, cancer testes antigens, immune-modulatory signaling pathways. Mol Cancer Ther. 2021;20:1422\u201330.","journal-title":"Mol Cancer Ther"},{"key":"1464_CR252","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/ng.3889","volume":"49","author":"D Brocks","year":"2017","unstructured":"Brocks D, Schmidt CR, Daskalakis M, Jang HS, Shah NM, Li D, et al. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nat Genet. 2017;49:1052\u201360.","journal-title":"Nat Genet"},{"key":"1464_CR253","doi-asserted-by":"publisher","first-page":"eaau5516","DOI":"10.1126\/scitranslmed.aau5516","volume":"10","author":"CM Laumont","year":"2018","unstructured":"Laumont CM, Vincent K, Hesnard L, Audemard E, Bonneil E, Laverdure JP, et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med. 2018;10:eaau5516.","journal-title":"Sci Transl Med"},{"key":"1464_CR254","first-page":"1766","volume":"54","author":"J Weber","year":"1994","unstructured":"Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2\u2032-deoxycytidine. Cancer Res. 1994;54:1766\u201371.","journal-title":"Cancer Res"},{"key":"1464_CR255","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11060-008-9732-0","volume":"92","author":"S Oi","year":"2009","unstructured":"Oi S, Natsume A, Ito M, Kondo Y, Shimato S, Maeda Y, et al. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2\u2032-deoxycytidine in glioma cells. J Neuro-Oncol. 2009;92:15\u201322.","journal-title":"J Neuro-Oncol"},{"key":"1464_CR256","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/00002371-200103000-00010","volume":"24","author":"TS Weiser","year":"2001","unstructured":"Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother. 2001;24:151\u201361.","journal-title":"J Immunother"},{"key":"1464_CR257","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1124\/mol.109.056291","volume":"76","author":"Q Li","year":"2009","unstructured":"Li Q, Bartlett DL, Gorry MC, O'Malley ME, Guo ZS. Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol. 2009;76:1072\u201381.","journal-title":"Mol Pharmacol"},{"key":"1464_CR258","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1476-4598-10-63","volume":"10","author":"Q Li","year":"2011","unstructured":"Li Q, O'Malley ME, Bartlett DL, Guo ZS. Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth. Mol Cancer. 2011;10:63.","journal-title":"Mol Cancer"},{"key":"1464_CR259","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1158\/0008-5472.CAN-05-3020","volume":"66","author":"ZS Guo","year":"2006","unstructured":"Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, et al. De novo induction of a cancer\/testis antigen by 5-aza-2\u2032-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 2006;66:1105\u201313.","journal-title":"Cancer Res"},{"key":"1464_CR260","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21:1433\u201342.","journal-title":"Lancet Oncol"},{"key":"1464_CR261","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder M, Schoffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21:1423\u201332.","journal-title":"Lancet Oncol"},{"key":"1464_CR262","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","volume":"1","author":"RA Juergens","year":"2011","unstructured":"Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011;1:598\u2013607.","journal-title":"Cancer Discov"},{"key":"1464_CR263","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1158\/1078-0432.CCR-18-3133","volume":"25","author":"MM Gounder","year":"2019","unstructured":"Gounder MM, Zhu G, Roshal L, Lis E, Daigle SR, Blakemore SJ, et al. Immunologic correlates of the abscopal effect in a SMARCB1\/INI1-negative poorly differentiated chordoma after EZH2 inhibition and radiotherapy. Clin Cancer Res. 2019;25:2064\u201371.","journal-title":"Clin Cancer Res"},{"key":"1464_CR264","doi-asserted-by":"publisher","unstructured":"Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. 2021. https:\/\/doi.org\/10.1111\/febs.15750.","DOI":"10.1111\/febs.15750"},{"key":"1464_CR265","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-017-0358-y","volume":"9","author":"R Mazzone","year":"2017","unstructured":"Mazzone R, Zwergel C, Mai A, Valente S. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Clin Epigenetics. 2017;9:59.","journal-title":"Clin Epigenetics"},{"key":"1464_CR266","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrd.2016.256","volume":"16","author":"SX Pfister","year":"2017","unstructured":"Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16:241\u201363.","journal-title":"Nat Rev Drug Discov"},{"key":"1464_CR267","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd.2016.185","volume":"15","author":"DF Tough","year":"2016","unstructured":"Tough DF, Tak PP, Tarakhovsky A, Prinjha RK. Epigenetic drug discovery: breaking through the immune barrier. Nat Rev Drug Discov. 2016;15:835\u201353.","journal-title":"Nat Rev Drug Discov"},{"key":"1464_CR268","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.it.2020.06.002","volume":"41","author":"L Villanueva","year":"2020","unstructured":"Villanueva L, Alvarez-Errico D, Esteller M. The contribution of epigenetics to cancer immunotherapy. Trends Immunol. 2020;41:676\u201391.","journal-title":"Trends Immunol"},{"key":"1464_CR269","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13046-021-01974-y","volume":"40","author":"GH Li","year":"2021","unstructured":"Li GH, Qu Q, Qi TT, Teng XQ, Zhu HH, Wang JJ, et al. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance. J Exp Clin Cancer Res. 2021;40:174.","journal-title":"J Exp Clin Cancer Res"},{"key":"1464_CR270","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","volume":"12","author":"L Garcia-Martinez","year":"2021","unstructured":"Garcia-Martinez L, Zhang Y, Nakata Y, Chan HL, Morey L. Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021;12:1786.","journal-title":"Nat Commun"},{"key":"1464_CR271","doi-asserted-by":"publisher","first-page":"992","DOI":"10.3389\/fonc.2020.00992","volume":"10","author":"A Quagliano","year":"2020","unstructured":"Quagliano A, Gopalakrishnapillai A, Barwe SP. Understanding the mechanisms by which epigenetic modifiers avert therapy resistance in cancer. Front Oncol. 2020;10:992.","journal-title":"Front Oncol"},{"key":"1464_CR272","doi-asserted-by":"crossref","unstructured":"Guo L, Lee YT, Zhou Y, Huang Y. Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Semin Cancer Biol. 2021; Online ahead of print.","DOI":"10.1016\/j.semcancer.2020.12.022"},{"key":"1464_CR273","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","volume":"17","author":"D Morel","year":"2020","unstructured":"Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. 2020;17:91\u2013107.","journal-title":"Nat Rev Clin Oncol"},{"key":"1464_CR274","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","volume":"19","author":"SJ Hogg","year":"2020","unstructured":"Hogg SJ, Beavis PA, Dawson MA, Johnstone RW. Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov. 2020;19:776\u2013800.","journal-title":"Nat Rev Drug Discov"},{"key":"1464_CR275","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","volume":"6","author":"J Cao","year":"2020","unstructured":"Cao J, Yan Q. Cancer epigenetics, tumor immunity, and immunotherapy. Trends Cancer. 2020;6:580\u201392.","journal-title":"Trends Cancer"},{"key":"1464_CR276","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cbpa.2020.04.008","volume":"57","author":"FP Cossio","year":"2020","unstructured":"Cossio FP, Esteller M, Berdasco M. Towards a more precise therapy in cancer: exploring epigenetic complexity. Curr Opin Chem Biol. 2020;57:41\u20139.","journal-title":"Curr Opin Chem Biol"},{"key":"1464_CR277","doi-asserted-by":"publisher","first-page":"eaat7807","DOI":"10.1126\/scitranslmed.aat7807","volume":"10","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez-Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10:eaat7807.","journal-title":"Sci Transl Med"},{"key":"1464_CR278","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.","journal-title":"Front Immunol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01464-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-021-01464-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01464-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T01:10:23Z","timestamp":1676077823000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-021-01464-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":278,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1464"],"URL":"https:\/\/doi.org\/10.1186\/s12943-021-01464-x","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"9 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors are consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"171"}}